Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)(ORIGIN) | completed | Phase 3 | 450 | CelgeneINDUSTRY | 27 | Jul 9, 2019 | clinicaltrials |
| NCT02213263 | A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) | completed | Phase 3 | 394 | PfizerINDUSTRY | 30 | Jun 20, 2019 |
| clinicaltrials |
| NCT00210353 | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma | completed | Phase 3 | 454 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 6 | Jun 6, 2019 | clinicaltrials |
| NCT00262795 | Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 3 | 206 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT00275054 | Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | completed | Phase 3 | 825 | German CLL Study GroupOTHER | 3 | May 23, 2019 | clinicaltrials |
| NCT00276848 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia | completed | Phase 3 | 375 | German CLL Study GroupOTHER | 2 | May 23, 2019 | clinicaltrials |
| NCT01539512 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 220 | Gilead SciencesINDUSTRY | 5 | May 14, 2019 | clinicaltrials |
| NCT00038090 | Thalidomide-Dexamethasone for Multiple Myeloma | completed | Phase 2 / Phase 3 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038233 | Thalidomide for Multiple Myeloma | completed | Phase 3 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01908621 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients. | completed | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00718549 | A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) | completed | Phase 3 | 128 | Hoffmann-La RocheINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT00232934 | Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients | completed | Phase 3 | 400 | Gruppo Italiano per lo Studio del Mieloma MultiploOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01973387 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | completed | Phase 3 | 160 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 24, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT00281892 | Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 97 | German CLL Study GroupOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00921414 | Mantel Cell Lymphoma Efficacy of Rituximab Maintenance | completed | Phase 3 | 299 | French Innovative Leukemia OrganisationOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | completed | Phase 3 | 447 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 7 | Feb 5, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT00891384 | Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 194 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY | 21 | Jan 19, 2018 | clinicaltrials |
| NCT03402295 | Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation(GBRAM003r) | completed | Phase 3 | 311 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 0 | Jan 18, 2018 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT00083915 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | completed | Phase 3 | 97 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01701232 | Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma | completed | Phase 3 | 174 | BiocadINDUSTRY | 5 | Nov 6, 2017 | clinicaltrials |
| NCT00056160 | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 353 | CelgeneINDUSTRY | 2 | Oct 19, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT01916252 | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old(GEM2012MENOS65) | completed | Phase 3 | 460 | PETHEMA FoundationOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT01500083 | Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia(BENDACT) | completed | Phase 3 | 90 | Lundbeck Canada Inc.INDUSTRY | 1 | Aug 14, 2017 | clinicaltrials |
| NCT00355199 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | completed | Phase 3 | 246 | Gruppo Italiano Terapie Innovative nei LinfomiOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00090051 | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | completed | Phase 3 | 552 | Hoffmann-La RocheINDUSTRY | 17 | Aug 1, 2017 | clinicaltrials |
| NCT00801281 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.(PLRG4) | completed | Phase 3 | 250 | Polish Lymphoma Research GroupNETWORK | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma(FOCUS) | completed | Phase 3 | 315 | AmgenINDUSTRY | 19 | May 2, 2017 | clinicaltrials |
| NCT00025259 | Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | completed | Phase 3 | 1,734 | Children's Oncology GroupNETWORK | 7 | Apr 12, 2017 | clinicaltrials |
| NCT00097981 | A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 225 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00732641 | Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | completed | Phase 3 | 244 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2017 | clinicaltrials |
| NCT00140582 | Primary Rituximab and Maintenance | completed | Phase 3 | 1,217 | Lymphoma Study AssociationOTHER | 12 | Mar 13, 2017 | clinicaltrials |
| NCT01277016 | A Trial for Systemic Light-chain (AL) Amyloidosis(EMN-03) | completed | Phase 3 | 110 | European Myeloma Network B.V.NETWORK | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01580228 | A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) | completed | Phase 3 | 44 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 23, 2017 | clinicaltrials |
| NCT01910987 | Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib(OPTIMRETREAT) | completed | Phase 3 | 80 | Janssen-Cilag International NVINDUSTRY | 11 | Feb 17, 2017 | clinicaltrials |
| NCT00405756 | A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | completed | Phase 3 | 459 | Celgene CorporationINDUSTRY | 22 | Jan 11, 2017 | clinicaltrials |
| NCT00254163 | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | completed | Phase 3 | 184 | US Oncology ResearchINDUSTRY | 1 | Nov 3, 2016 | clinicaltrials |
| NCT00046683 | Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | completed | Phase 3 | 284 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jul 28, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 9, 2019source: clinicaltrials